Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
By A. Di Leo, G. Jerusalem, L. Petruželka, R. Torres, I. Bondarenko, R. Khasanov, D. Verhoeven, J. Pedrini, I. Smirnova, M. Lichinitser and 5 more. Journal of Clinical Oncology, 2010
606 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/96209f70df820dd1e795bdd809831ab8b9978a1b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer (2014, result): “This might explain in part the results of the CONFIRM trial in which a higher dose of fulvestrant improved progression-free survival (39).”
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017, background): “To the best of our knowledge, the ORR achieved in patients who received abemaciclib plus fulvestrant is the highest observed in a phase III study of patients whose disease had progressed while they were receiving prior ET.(5,22,24,26) Fewer patients in the abemaciclib arm experienced disease progres”
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, background): “1-month difference in median OS compared with fulvestrant 250 mg [80].”